Which treatment for high-risk patients with DLBCL?

被引：0
|
作者：
Coiffier, Bertrand [1 ]
机构：
[1] Ctr Hosp Lyon Sud, Hosp Civils Lyon, F-69310 Pierre Benite, France
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 12期
关键词：
HIGH-DOSE CHEMOTHERAPY; B-CELL LYMPHOMA; OPEN-LABEL; CHOP CHEMOTHERAPY; YOUNG-PATIENTS; PHASE-3; TRIAL; RITUXIMAB; DSHNHL;
D O I：
10.1016/S1470-2045(12)70507-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1180 / 1182
页数：4
相关论文
共 50 条
  • [31] Treatment of femoral pseudoaneurysms with endograft in high-risk patients
    Derom, A
    Nout, E
    EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2005, 30 (06) : 644 - 647
  • [32] Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
    Mora, Jaume
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (05) : 647 - 653
  • [33] Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis
    Jeong, Hyehyun
    Cho, Hyungwoo
    Kim, Hyeyeong
    Chae, Heejung
    Lee, Jung-Bok
    Lee, Kyoungmin
    Kim, Shin
    Lee, Sang-wook
    Ryu, Jin-Sook
    Kim, Kyung Won
    Chae, Eun Jin
    Huh, Jooryung
    Park, Chan-Sik
    Yoon, Dok Hyun
    Suh, Cheolwon
    BLOOD ADVANCES, 2021, 5 (08) : 2142 - 2152
  • [34] WHICH PHYSICIANS ARE AT HIGH-RISK FOR NEEDLESTICK INJURIES
    MANSOUR, AM
    AMERICAN JOURNAL OF INFECTION CONTROL, 1990, 18 (03) : 208 - 210
  • [35] Determining Treatment for Older Patients with High-Risk MDS and AML: Which Factors Predict Optimal Quality of Life?
    Tinsley-Vance, Sara M.
    Small, Brent J.
    McMillan, Susan C.
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    BLOOD, 2016, 128 (22)
  • [36] Which treatment should patients with high-risk T1G3 bladder cancer receive?
    Huang, George J.
    Stein, John P.
    NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (08): : 414 - 415
  • [37] Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup
    Jiang, Shiyu
    Qin, Yan
    Jiang, Hongxin
    Liu, Biao
    Shi, Jianming
    Meng, Fanlu
    Liu, Peng
    Yang, Jianliang
    Yang, Sheng
    He, Xiaohui
    Zhou, Shengyu
    Gui, Lin
    Liu, Hao
    Lin, Jing
    Han Han-Zhang
    Shi, Yuankai
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (09) : 2611 - 2620
  • [38] Which treatment should patients with high-risk T1G3 bladder cancer receive?
    George J Huang
    John P Stein
    Nature Clinical Practice Urology, 2008, 5 : 414 - 415
  • [39] Which Is the Best Option to Relieve Symptoms of Cholecystitis in High-Risk Cirrhotic Patients?
    Bonato, Giulia
    Forti, Edoardo
    Mutignani, Massimiliano
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (09) : 1919 - 1920
  • [40] Treatment of High-Risk Neuroblastoma
    Hizhnikov, A.
    Kazancev, A.
    Kerimov, P.
    Pimenov, R.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S447 - S447
12345